Aug 2026· Journal of the American Medical Association (JAMA)· 0 citations· 25 references
Medicine
TL;DR
Reclassification results support selective use of CAC in those with borderline to intermediate risk estimated by the PREVENT-ASCVD equations, and in some groups, did not change model discrimination and reclassification.
Abstract
Importance
The 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline newly recommends selective use of coronary artery calcium (CAC) scoring based on a 10-year risk of 3% to less than 10% estimated with the Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) atherosclerotic cardiovascular disease (ASCVD) equations. However, the utility of CAC scoring alongside the PREVENT equations for ASCVD risk estimation is not known.
Objective
To determine the change in predictive utility when adding CAC scores to the PREVENT-ASCVD equations.
Design, Setting, and Participants
Longitudinal observational cohort study conducted at 6 sites in the United States and enrolling adult participants aged 45 to 79 years without ASCVD at baseline in the Multi-Ethnic Study of Atherosclerosis.
Exposures
Ten-year ASCVD risk with the PREVENT-ASCVD equations before and after adding CAC scores.
Main Outcomes
Performance metrics for estimation of risk of fatal and nonfatal ASCVD, assessed using the Harrell C statistic, calibration, and net reclassification improvement (NRI) for newly defined ASCVD risk categories: low (<3%); borderline (3% to <5%); intermediate (5% to <10%); and high (≥10%).
Results
A total of 6098 participants were included. At baseline, participant mean age was 61.4 (SD, 9.6) years, 52% were female, mean estimated 10-year ASCVD risk was 6.4% (SD, 4.8%) with the PREVENT-ASCVD base equations, and 49% had a CAC score greater than 0. During 10 years of follow-up, 366 (6%) experienced an ASCVD event. The Harrell C statistic for the PREVENT-ASCVD base equations was 0.73 (95% CI, 0.70-0.75). After adding CAC to the PREVENT-ASCVD base equations, the change in Harrell C statistic was 0.02 (95% CI, 0.01-0.03), and the categorical NRI was 0.095 (95% CI, 0.053-0.137). The calibration slope for the PREVENT-ASCVD base equations was 1.09 (95% CI, 0.93-1.25), and for the PREVENT-ASCVD base plus CAC equations was 0.92 (95% CI, 0.81-1.03). Among those at borderline risk, incident ASCVD occurred in 1.9% of those with CAC score of 0, 3.9% with CAC greater than 0 and less than 100, 7.4% with CAC 100 or greater and less than 300, and 14.3% with CAC 300 or greater.
Conclusions and Relevance
Among US adults aged 45 to 79 years, addition of CAC score to the PREVENT-ASCVD equations across all risk groups overall only modestly improved and, in some groups, did not change model discrimination and reclassification. Reclassification results support selective use of CAC in those with borderline to intermediate risk estimated by the PREVENT-ASCVD equations.
The authors review the evolution of CAC across the 2007, 2018, and 2026 ACC/AHA guideline documents and discuss the expanding role of CAC in personalized cardiovascular prevention.
K. Irannejad, R. Mora, Srikanth Krishnan et al.· JACC Cardiovascular Imaging· 1 citation
The American Heart Association's PREVENT equations offer a contemporary, race-free alternative to the Pooled Cohort Equations (PCE), incorporating kidney function to estimate 10- and 30-year risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, and total CVD. PREVENT-ASCVD is now recommended for prima...
I. Mortada, Ebrahim Adel Elkolaly, Aaron W. Lee et al.· Current problems in cardiolo...· 0 citations
Higher Framingham risk scores were associated with poorer tread mill performance, and combining cardiovascular risk assessment with treadmill exercise testing may facilitate identification of cardiovascular risk.
Manish Kumar S, N. M, A. Kalpana· Indian Journal of Public Hea...· 0 citations
Treatment paradigms emphasize early intensification of therapy and addition of non-statin agents, and polygenic risk scoring and RNA-based therapies may offer opportunities to identify and treat those at highest residual risk.
Andrew Carlson, Zaid A. Zayyad, Stefanie Driesenga et al.· Cardiology and Therapy· 0 citations
AIM
Coronary artery disease (CAD) remains the leading cause of morbidity and mortality globally. Polygenic Risk Scores (PRS) have been trained against major adverse cardiovascular outcomes (MACE) in large cohorts. Few studies have examined the effectiveness of these CAD MACE PRS tools in detecting individuals with subc...
M. Gray, D. Strbenac, Daniel Brieger et al.· European Journal of Preventi...· 0 citations
A practical, evidence-based synthesis of Lp(a) biology, contemporary guideline recommendations, integrated risk stratification using PREVENT and CAC, current management, and emerging Lp(a)-targeted therapies for use across primary care and cardiology practice are provided.
A. Syed, Samuel Michalak, I. Potulapati et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.